FDA Soliciting Broad Range Of Comments From Industry On Regulatory Reform
FDA is addressing regulatory reform as part of President Trump's "two-for-one" executive order, and seeks industry comments to supplement the effort.
You may also be interested in...
Secretary Price will be succeeded on an acting basis by HHS acting assistant secretary for health Donald Wright, and everything from development of the executive order on drug pricing to pending Medicare reimbursement experiments could see a pause as part of the transition.
No additional hiring is expected as US agency announces formal plan to return orphan review times to the original 90-day goal.
Draft order wants "comprehensive review" to find regulations that that "unnecessarily increases expenses" for patients, researchers, and manufacturers.